Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Lebrikizumab for severe asthma – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Asthma is a long-term condition that affects the lungs and breathing. People with asthma may have coughing, wheezing, chest tightness and breathlessness. Most people can control their symptoms with treatment for most of the time, but some people still have symptoms despite treatment or may suffer from more sudden 'asthma attacks'. Severe asthma attacks can lead to hospitalisation, and on rare occasions can be life threatening.
Lebrikizumab is a new drug to help people with severe asthma and needs to be injected under the skin. Some studies have suggested that lebrikizumab can help control severe asthma when other drugs have failed to do so. More studies are trying to show how well lebrikizumab works and whether it is safe to use.
If lebrikizumab is licenced for use in the UK, it could be a new treatment option for patients with severe asthma. Indexing Status Subject indexing assigned by CRD MeSH Anti-Asthmatic Agents; Antibodies, Monoclonal; Asthma; Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000532 Date abstract record published 15/03/2016 |